Friday, 16 October 2026European Markets

COFACE Stock Rises 9% So Far On Friday, Outperforms Market

Loading stream...

(vianews) - shares of coface (cac 40: cofa.pa) rose 9.73% to €13.31 at 14:53 est on friday, after four sequential sessions in a row of losses. cac 40 is jumping 0.39% to €7,257.49, after four successive sessions in a row of losses. this seems, so far, a somewhat up trend exchanging session today.

coface's last close was €12.13, 16% below its 52-week high of €14.44.

about coface

coface sa, through its subsidiaries, provides credit insurance products and related services for microenterprises, small and medium enterprises, mid-market companies, international corporations, financial institutions, and clients of distribution partners. the company offers credit insurance products to protect companies against default on payment of its trade receivables. it also provides integrated credit management solutions comprising credit insurance, single risk insurance, business information and debt collection services for insured and uninsured businesses; and factoring services, as well as contract and environmental surety, customs and excise, and legal bonds; and payment guarantees. in addition, the company offers business information services through its icon portal, an information services web platform. it operates in western europe, northern europe, central and eastern europe, the mediterranean and africa, north america, latin america, and the asia-pacific. coface sa was founded in 1946 and is headquartered in bois-colombes, france.

earnings per share

as for profitability, coface has a trailing twelve months eps of €1.9.

pe ratio

coface has a trailing twelve months price to earnings ratio of 7.01. meaning, the purchaser of the share is investing €7.01 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.81%.

more news about coface (cofa.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com